Malignant Ovarian Epithelial Tumor

subtype

Identifier: CI-CAN-00001157
Entity page: /cancer/malignant-ovarian-epithelial-tumor ↗
Edges: 1,174

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Ovarian Epithelial Tumor approved for …APPROVED_FORderived4 of 4
← approved for	Carboplatinsmall molecule FDA (US) · approved · 2025-08-08 · As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma.	—	approved	Ovarian Carcinoma	1	Regulatory	openfda	graph →
← approved for	Carboplatinsmall molecule

Malignant Ovarian Epithelial Tumor altered in cohorts of …ALTERED_INderived15 of 117show all (up to 200)
← altered in cohorts of	TP53 483 / 603 cases (80 %) · ssm · TCGA-OV · largest of 6 cohorts	—	—	Ovarian Serous Cystadenocarcinoma	6	Observed	gdc	graph →
← altered in cohorts of	MYC 455 / 603 cases (75 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM135B 449 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	POU5F1B 449 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTRT3 447 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCY8 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AGO2 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC34 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MYNN 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PTK2 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GPR20 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GSDMC 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRATD2 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC31 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRIQ4 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →

Malignant Ovarian Epithelial Tumor altered in cohorts of …ALTERED_INderived15 of 117show all (up to 200)

← altered in cohorts of

TP53

483 / 603 cases (80 %) · ssm · TCGA-OV · largest of 6 cohorts

—

Ovarian Serous Cystadenocarcinoma

Observed

Malignant Ovarian Epithelial Tumor investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 156show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 109 trials (36 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	109	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 86 trials (27 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	86	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 71 trials (29 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	71	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 38 trials (21 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 37 trials (16 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 32 trials (19 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 29 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 28 trials (11 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 27 trials (10 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 24 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 19 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 17 trials (8 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 12 trials (4 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 12 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Veliparibsmall molecule 11 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Epithelial Tumor	11	Observed	clinicaltrials	graph →

Malignant Ovarian Epithelial Tumor studied in …STUDIED_INderived10 of 897show all (up to 200)
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 897 trials mapped (307 active)	—	—	Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · condition mapped ALIAS · 897 trials mapped (307 active)	—	—	Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05956093NA · active not recruiting 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study · condition mapped ONTOLOGY_EXACT · 897 trials mapped (307 active)	—	—	High-Grade Serous Ovarian Cancer	1	Observed	clinicaltrials	graph →
→ studied in	NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 897 trials mapped (307 active)	—	—	Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06619236Phase 3 · active not recruiting Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 897 trials mapped (307 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 897 trials mapped (307 active)	—	—	Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03564340Phase 1/Phase 2 · recruiting Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers · condition mapped ONTOLOGY_EXACT · 897 trials mapped (307 active)	—	—	Low-Grade Serous Ovarian Cancer	1	Observed	clinicaltrials	graph →
→ studied in	NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped ONTOLOGY_EXACT · 897 trials mapped (307 active)	—	—	Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06172478Phase 2 · recruiting A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 897 trials mapped (307 active)	—	—	Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 897 trials mapped (307 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains